Source:http://linkedlifedata.com/resource/pubmed/id/20071587
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
2010-2-22
|
| pubmed:abstractText |
Coinfection with human T-cell lymphotropic virus type 2 (HTLV-2) and human immunodeficiency virus type 1 (HIV-1) has been reported to have either a slowed disease course or to have no effect on progression to AIDS. In this study, we generated a coinfection animal model and investigated whether HTLV-2 could persistently infect macaques, induce a T-cell response, and impact simian immunodeficiency virus SIV(mac251)-induced disease. We found that inoculation of irradiated HTLV-2-infected T cells into Indian rhesus macaques elicited humoral and T-cell responses to HTLV-2 antigens at both systemic and mucosal sites. Low levels of HTLV-2 provirus DNA were detected in the blood, lymphoid tissues, and gastrointestinal tracts of infected animals. Exposure of HTLV-2-infected or naïve macaques to SIV(mac251) demonstrated comparable levels of SIV(mac251) viral replication, similar rates of mucosal and peripheral CD4(+) T-cell loss, and increased T-cell proliferation. Additionally, neither the magnitude nor the functional capacity of the SIV-specific T-cell-mediated immune response was different in HTLV-2/SIV(mac251) coinfected animals versus SIV(mac251) singly infected controls. Thus, HTLV-2 targets mucosal sites, persists, and importantly does not exacerbate SIV(mac251) infection. These data provide the impetus for the development of an attenuated HTLV-2-based vectored vaccine for HIV-1; this approach could elicit persistent mucosal immunity that may prevent HIV-1/SIV(mac251) infection.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
1098-5514
|
| pubmed:author |
pubmed-author:AndresenVibekeV,
pubmed-author:CecchinatoValentinaV,
pubmed-author:ChungHye KyungHK,
pubmed-author:FeniziaClaudioC,
pubmed-author:FerrariMaria GraziaMG,
pubmed-author:FranchiniGenoveffaG,
pubmed-author:GordonShari NSN,
pubmed-author:HeraudJean MichelJM,
pubmed-author:JacobsonStevenS,
pubmed-author:JonesKathryn SKS,
pubmed-author:LeeTzong-HaeTH,
pubmed-author:MaZhong-MinZM,
pubmed-author:MahieuxRenaudR,
pubmed-author:MillerChristopher JCJ,
pubmed-author:MurphyEdward LEL,
pubmed-author:ParksRobyn WashingtonRW,
pubmed-author:RuscettiFrancis WFW,
pubmed-author:VenzonDavidD,
pubmed-author:WeissmanAnna RAR,
pubmed-author:ZaffiriLorenzoL
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
84
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
3043-58
|
| pubmed:dateRevised |
2010-9-2
|
| pubmed:meshHeading |
pubmed-meshheading:20071587-Animals,
pubmed-meshheading:20071587-CD4-Positive T-Lymphocytes,
pubmed-meshheading:20071587-Dendritic Cells,
pubmed-meshheading:20071587-Genome, Viral,
pubmed-meshheading:20071587-HIV Infections,
pubmed-meshheading:20071587-HIV-1,
pubmed-meshheading:20071587-HTLV-II Infections,
pubmed-meshheading:20071587-Human T-lymphotropic virus 2,
pubmed-meshheading:20071587-Humans,
pubmed-meshheading:20071587-Immunity,
pubmed-meshheading:20071587-Intestinal Mucosa,
pubmed-meshheading:20071587-Lymphocyte Activation,
pubmed-meshheading:20071587-Lymphoid Tissue,
pubmed-meshheading:20071587-Macaca mulatta,
pubmed-meshheading:20071587-Simian immunodeficiency virus,
pubmed-meshheading:20071587-Viral Load
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
Preexisting infection with human T-cell lymphotropic virus type 2 neither exacerbates nor attenuates simian immunodeficiency virus SIVmac251 infection in macaques.
|
| pubmed:affiliation |
Animal Models and Retroviral Vaccines Section, National Cancer Institute, NIH,Bethesda, Maryland 20892, USA.
|
| pubmed:publicationType |
Journal Article
|